COLL — Q2 2026 Financial Report Analysis

Collegium's second quarter of 2026 is two stories pulling in opposite directions. Its ADHD drugs are growing fast — Jornay PM revenue rose 41% and the newly bought Azstarys added $12.9 million in its first seven weeks — while its older opioid pain products are shrinking as generic copies of Nucynta reach the market. Product revenue rose 6.3% to $199.9 million, but the company swung to a GAAP net loss of $15.1 million because of $24.1 million of one-time costs from the Azstarys deal, and it cut its full-year revenue guidance by $40 million at the midpoint.

At a glance

• $46.1 million Jornay PM revenue, up 41% — the ADHD drug Collegium bought in 2024 is now its fastest-growing product, with a record 30,000+ prescribers, up 17.6%.
• Nucynta revenue down 24% to $35.2 million — generic competition arrived this year, and the cheaper "authorized generic" Collegium licensed to Hikma brought in only $5.1 million against a $16.3 million drop in the branded drug.
• Full-year revenue guidance cut to $825–855 million (from $865–895 million) — the company blames lower-than-expected pricing on the Nucynta generics, even as it raised the Azstarys outlook.

What happened in the quarter

Collegium is a specialty drugmaker that sells a handful of branded medicines in the US. Until 2024 it was almost entirely a pain-management company (opioid painkillers Belbuca, Xtampza ER and Nucynta). It has since committed about $1 billion in purchase consideration to buy two ADHD drugs — Jornay PM (via the Ironshore deal, September 2024) and Azstarys (closed May 12, 2026, for about $655.6 million in cash plus up to $135 million in milestone payments) — to build a growth business while the pain franchise matures.

"Gross margin before amortization" is what's left of each sales dollar after the cost of making the pills; it stays near 87% because branded drugs are cheap to produce. The big gap between that and the 1.9% operating margin (profit after running the business, before interest and tax) is mostly accounting for past acquisitions — $63.0 million of "intangible asset amortization", a non-cash charge that spreads the price paid for drug rights over their expected life — plus $106.6 million of selling, general and administrative costs.

Product by product

• Jornay PM (+$13.4 million): the 10-Q attributes the gain to "higher sales volume, lower gross-to-net adjustments related to provisions for co-pay program incentives and product returns, and higher gross price". "Gross-to-net" is the gap between a drug's list price and what the company actually keeps after rebates to insurers, discounts and co-pay assistance; less of that leakage meant more revenue per prescription. Prescriptions grew 13.1%, so most of the revenue growth came from better net pricing and lower deductions rather than more prescriptions.
• Belbuca (+$5.1 million): "higher gross price and higher sales volume", partly offset by bigger rebates and chargebacks.
• Xtampza ER (−$7.6 million): lower volume and bigger rebates. About $2.4 million of the drop is a comparison quirk: Q2 2025 benefited from rebate settlements that did not repeat. Excluding that, the decline is closer to 10%.
• Nucynta (−$11.1 million): Nucynta ER's market exclusivity ended in December 2025, a generic version of Nucynta IR was approved in January 2026, and Collegium's partner Hikma launched authorized generics (the same drug sold under a generic label, with Collegium taking a share) in February and March. Branded Nucynta fell $16.3 million; the authorized generics recovered only $5.2 million of it.

What the headline numbers hide

Without the acquisition, sales were flat. Strip out Azstarys's $12.9 million and product revenue was $187.0 million, 0.5% below last year. Jornay PM and Belbuca's growth ($18.5 million combined) was almost exactly cancelled by the declines in Nucynta, Xtampza ER and Symproic ($19.4 million). The 6.3% headline growth is bought, not earned — which is the point of the deal, but worth being clear about.

The GAAP loss is mostly deal costs. SG&A rose $33.0 million, of which $23.2 million was acquisition-related (bankers, lawyers, integration consultants) and about $3.6 million was executive-transition costs (accelerated stock awards and severance). Cost of goods also included $5.4 million of "inventory step-up" — Azstarys inventory was booked at fair value when bought, so selling it shows a lower profit than it will once that inventory is used up. These items should fade over the next few quarters; the company says it expects more integration costs through the rest of 2026.

Adjusted EPS growth leans on a lower tax rate. Collegium's own "adjusted" earnings exclude amortization, stock-based pay ($14.5 million), acquisition costs and the inventory step-up, which turns a $15.1 million loss into $75.4 million of profit. That measure grew 14.3% per share, but the tax rate the company applies to it fell from 25.5% to 17.3%. Pre-tax, adjusted earnings grew about 6%; at last year's tax rate, adjusted EPS would have been roughly $1.70, almost unchanged. Adjusted EBITDA (+8.4%) is the cleaner read of operating progress.

Cash generation held up. Operating cash flow was $71.3 million in the quarter and $128.4 million for the first half, essentially level with $127.8 million a year earlier, against a first-half GAAP net loss of $0.6 million. The cash is real; the GAAP loss is mainly non-cash amortization and one-off costs.

The balance-sheet jumps are the acquisition, not stuffed channels. Accounts receivable rose from $211.3 million to $285.1 million and inventory from $40.9 million to $113.3 million since December, but the purchase accounting shows $58.5 million of receivables and $69.9 million of inventory (including a $35.3 million fair-value step-up) came in with Azstarys. Allowing for that, neither grew faster than sales.

Debt roughly doubled. To fund Azstarys, Collegium drew a $300 million delayed-draw term loan and used about $355.6 million of its own cash and investments. Cash and marketable securities fell from $386.7 million to $129.5 million, while term-loan debt rose from $571.1 million to $852.8 million (plus $238.7 million of convertible notes due 2029). Net debt — borrowings minus cash — rose from about $423 million to about $962 million, roughly 2.1 times the midpoint of the new adjusted-EBITDA guidance. That is manageable, but the term loan floats with SOFR plus 2.75–3.75% and is not hedged, and $55 million of principal falls due over the next 12 months.

Buybacks restarted after the quarter. Collegium bought no shares under its $150 million program in the first half. On August 12 it signed a $50 million accelerated share repurchase with Jefferies, receiving an initial 1,556,420 shares at $25.70 — about 4.8% of the 32.5 million shares outstanding. That will lift per-share figures in the second half, but it is being funded while net debt sits near its peak.

Guidance went down, not up. Product revenue guidance fell to $825–855 million from $865–895 million, and adjusted EBITDA to $445–470 million from $475–500 million. The company attributes both cuts "largely" to lower-than-expected revenue from the Nucynta authorized generics "due to lower net pricing". Jornay PM guidance ($190–200 million) was kept and Azstarys guidance was raised to $65–75 million from $60–70 million.

Takeaway: Collegium is swapping a shrinking opioid business for a growing ADHD one, and Q2 shows both halves clearly: ADHD revenue rose 81% to $59.0 million, but underlying sales excluding the acquisition were flat and the Nucynta generic erosion was bad enough to cut full-year guidance by $40 million. The deal costs behind the GAAP loss are temporary; the Nucynta decline and the higher debt load are not.

Outlook

Management's updated 2026 guidance implies second-half product revenue of roughly $432–462 million, or about $216–231 million a quarter, up from $199.9 million in Q2. Most of that step-up should come from mechanics already in place: a full quarter of Azstarys (the raised $65–75 million full-year range implies about $52–62 million in the second half), the back-to-school season that typically lifts ADHD prescriptions, and Jornay PM, whose $190–200 million target requires $105–115 million in the second half against $85.0 million in the first.

Things to watch in Q3:

• Nucynta's floor. Nucynta IR's remaining pediatric exclusivity runs to January 3, 2027, after which further generic competition is possible. How fast branded Nucynta keeps falling is the main swing factor behind the guidance cut.
• Azstarys's run rate. The company's pro forma figures imply Azstarys sold roughly $19 million in the six weeks before closing; a full quarter of $26–31 million would be in line with guidance.
• GAAP earnings should improve mechanically. The Nucynta intangible is now fully amortized and Belbuca's will be during 2026, which removes a large non-cash charge, partly replaced by about $55 million a year of Azstarys amortization (a $635 million intangible over 11.6 years). With deal costs fading, GAAP profit should return even if sales are flat.
• Belbuca's patents. A new generic challenger, Ascent Pharmaceuticals, filed a challenge in June 2026 to a Belbuca patent that runs to December 2032; Collegium sued in July. Belbuca is now its largest product, so this litigation matters more than before.

Our read: the ADHD pivot is working on volume, and Jornay PM's 41% growth is genuine. But the company is now more leveraged and more dependent on a two-drug ADHD franchise to outrun opioid erosion, and the first guidance revision after the Azstarys close went the wrong way. Q3's back-to-school numbers will be the first fair test of whether the combined ADHD sales force can deliver the second-half ramp the guidance requires.